Amarantus BioScience
Biotechnology ResearchCalifornia, United States2-10 Employees
Amarantus BioScience Holdings is a biotechnology company focused on developing treatments and diagnostics for neurological disorders, regenerative medicine, and orphan diseases. Its portfolio includes a regenerative medicine program that grows autologous skin for treating severe burns and is advancing such therapies through Phase 2 studies under a CRADA with the US Army, alongside plans for a pivotal program targeting Giant Congenital Melanocytic Nevi, a rare pediatric condition. The company also holds licenses to drug candidates and licenses tied to neurotrophic factors, pursuing MANF-based products for brain and eye disorders, as well as several diagnostic and biomarker assets, including MSPrecise for early multiple sclerosis identification and tests for Alzheimer’s and Parkinson’s diseases. Amarantus operates from Sunnyvale, California, and positions itself within the biotechnology research sector by combining investigative therapies with diagnostic tools. The firm aims to address unmet needs in neurology and related fields through its integrated approach to development and diagnostics, supported by collaborations and partnerships in its history.
1-888-653-2347 
support@leadiq.com 
